REGN Trading Analysis - 09/10/2026 04:17 PM — TRU-SENTIMENT

News Headlines & Context:

Recent news headlines for REGN (Regeneron Pharmaceuticals) include:

• Regeneron Pharmaceuticals, Inc. (REGN) announced positive results from its Phase 3 trial of aflibercept for the treatment of non-proliferative diabetic retinopathy (NPDR).
• The company reported that the trial met its primary endpoint, demonstrating a significant reduction in the risk of progression of NPDR.
• REGN's Board of Directors has authorized a $1.5 billion share repurchase program.

These headlines may relate to the technical and sentiment data, as positive clinical trial results and share buybacks can be seen as bullish catalysts for the stock.

Fundamental Analysis:

Revenue Growth: The provided fundamentals data shows that REGN has a total revenue of $15,534,700,000. However, the revenue growth rate is not provided.

Profit Margins: REGN has a profit margin of 27.86%, an operating margin of 24.74%, but the gross margin is not provided.

Earnings Per Share (EPS): The trailing EPS is $40.44.

P/E Ratio: The trailing P/E ratio is 19.97.

Valuation: The PEG ratio is not provided.

Key Fundamental Strengths/Concerns:

• Strengths: High profit margins, significant revenue.
• Concerns: No provided data on debt to equity, ROE, or free cash flow.

Analyst Consensus: Not provided.

The fundamentals suggest that REGN has a strong financial position, but some data is missing to make a comprehensive analysis.

Current Market Position:

Current Price: $793.26.

Recent Price Action: The daily history shows that REGN has been fluctuating between $792 and $806 over the past few days.

Key Support/Resistance:

• Support: $784.93 (Bollinger Band lower bound).
• Resistance: $851.39 (Bollinger Band upper bound).

Intraday Momentum: The minute bars show a slight downtrend in the last few minutes.

Technical Analysis:

SMA Trends:

• 5-day SMA: $816.48.
• 20-day SMA: $818.16.
• 50-day SMA: $748.32.

The stock is currently below the 5-day and 20-day SMAs, indicating a short-term downtrend.

RSI: 40.41, indicating a slightly oversold condition.

MACD: 17.23, with a bullish signal.

Bollinger Bands: The stock is currently near the lower bound of the Bollinger Bands.

30-day High/Low: The stock is currently near the lower end of its 30-day range.

True Sentiment Analysis:

Options Flow Sentiment: Balanced.

Call vs Put Dollar Volume: Call dollar volume: $223,320, Put dollar volume: $176,270.

The options flow sentiment is currently balanced, indicating no clear directional bias.

Key Price Levels:

25-Day Price Forecast:

REGN is projected for $805.00 to $825.00.

The projection is based on the current technical trends, momentum, and indicators. The stock is expected to fluctuate within the Bollinger Bands and move towards the 20-day SMA.

Defined Risk Strategy Recommendations:

Based on the price forecast, the following defined risk strategies are recommended:

• Bull Call Spread: Buy 1 call option with a strike price of $805, sell 1 call option with a strike price of $825, expiring on 2026-10-16.
• Iron Condor: Sell 1 call option with a strike price of $815, buy 1 call option with a strike price of $825, sell 1 put option with a strike price of $785, buy 1 put option with a strike price of $775, expiring on 2026-10-16.

These strategies align with the projected price range and provide a defined risk profile.

Risk Factors:

• Technical warning signs: The stock is currently near the lower bound of the Bollinger Bands.
• Sentiment divergences: The options flow sentiment is currently balanced.
• Volatility: The ATR is 19.82.

Summary & Conviction Level:

Overall Bias: Neutral.

Conviction Level: Medium.

One-line Trade Idea: REGN is expected to fluctuate within the Bollinger Bands.